Matthew Graham, MD
Internal Medicine · Moultrie, GANPI 1316385784
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Galderma Laboratories, L.p. at 27.3% of the total. Reporting peaked in 2021 at $236 and has fallen 74.7% since, to $60 in 2025.
Across 34 payments — averaging $22.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$207
- Merz North America, Inc.$199
- Johnson & Johnson$110
- AbbVie$103
- Melinta Therapeutics, LLC$47
- Pfizer$42
- plus $49 from 3 others
What the payments were for
- Food & beverage$757100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 9 | $207 |
| Merz North America, Inc. | 6 | $199 |
| Johnson & Johnson | 6 | $110 |
| AbbVie(2 entities) | 5 | $103 |
| Melinta Therapeutics, LLC | 2 | $47 |
| Pfizer | 3 | $42 |
| Novartis | 1 | $20 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
| AstraZeneca | 1 | $14 |
How this compares
$757 in reported general payments places this provider in the 60th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 11 | $90 |
| Prednisone | 21 | $52 |
| Doxycycline Hyclate | 12 | $50 |
| Atorvastatin Calcium | 13 | $49 |
| Amlodipine Besylate | 11 | $33 |
| Levofloxacin | 15 | $30 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Moultrie
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.